HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pohl, D. Articles by Hanefeld, F. Search for Related Content PubMed PubMed Citation Articles by Pohl, D. Articles by Hanefeld, F. Related Collections Related Article

Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a

From the Department of Pediatrics and Pediatric Neurology, Georg-August-University Goettingen, Goettingen, Germany.

Address correspondence and reprint requests to Dr. Daniela Pohl, Department of Pediatrics and Pediatric Neurology, Georg-August-University Goettingen, Robert-Koch-Strasse 40, 37075 Germany. E-mail: dpohl{at}med.uni-goettingen.de

The authors studied the tolerability of subcutaneous interferon beta-1a (IFNß-1a) in 51 patients with early-onset multiple sclerosis. The most frequent systemic adverse effects were flu-like symptoms in 65%. Laboratory abnormalities included asymptomatic leukopenia (27%) and elevated hepatic transaminases (35%). Treatment with IFNß-1a was safe and well tolerated in the majority of children and adolescents.

Related Article

March 8 Highlights
Neurology 2005 64: 772-773. [Full Text] [PDF]

This article has been cited by other articles:

				P. Huppke, W. Stark, C. Zurcher, B. Huppke, W. Bruck, and J. Gartner Natalizumab Use in Pediatric Multiple Sclerosis Arch Neurol, December 1, 2008; 65(12): 1655 - 1658. [Abstract] [Full Text] [PDF]

				H.L. Tremlett and J. Oger Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective Multiple Sclerosis, January 1, 2008; 14(1): 94 - 105. [Abstract] [PDF]

				S. Tenembaum, T. Chitnis, J. Ness, J. S. Hahn, and for the International Pediatric MS Study Group Acute disseminated encephalomyelitis Neurology, April 17, 2007; 68(16_suppl_2): S23 - S36. [Abstract] [Full Text] [PDF]

				A. L. Belman, T. Chitnis, C. Renoux, E. Waubant, and for the International Pediatric MS Study Group Challenges in the classification of pediatric multiple sclerosis and future directions Neurology, April 17, 2007; 68(16_suppl_2): S70 - S74. [Abstract] [Full Text] [PDF]

				P. F. Jenkins The Multiple Facets of Multiple Sclerosis Amer. Orthoptic Jrnl., January 1, 2007; 57(1): 69 - 78. [Abstract] [PDF]

				S. N. Tenembaum and M. J. Segura Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis Neurology, August 8, 2006; 67(3): 511 - 513. [Abstract] [Full Text] [PDF]

				B. Banwell, A. T. Reder, L. Krupp, S. Tenembaum, M. Eraksoy, B. Alexey, D. Pohl, M. Freedman, L. Schelensky, and I. Antonijevic Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis Neurology, February 28, 2006; 66(4): 472 - 476. [Abstract] [Full Text] [PDF]

				B. Banwell and H. Tremlett Coming of age: The use of immunomodulatory therapy in children with multiple sclerosis Neurology, March 8, 2005; 64(5): 778 - 779. [Full Text] [PDF]